Raymond James analyst Gary Nachman raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $75 from $68 and keeps a Strong Buy rating on the shares after hosting CEO Brett Monia as part of the firm’s BioPharma CEO Strategy Series. Ionis has shown it can execute well commercially with Tryngolza for familial chylomicronemia syndrome, which bodes well for the recent second wholly-owned launch of Dawnzera for hereditary angioedema where early physician/patient sentiment is positive/promising, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals Reports Positive Study Results for Zilganersen
- Ionis Pharmaceuticals reports zilganersen study met primary, secondary endpoints
- Ionis Pharmaceuticals: Strategic Positioning and Growth Potential with Olezarsen’s EU Approval and Promising sHTG Market Prospects
- Ionis Pharmaceuticals announces Tryngolza approval in European Union
- Arrowhead files complaint for declaratory judgment against Ionis